HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunomodulating tellurium compounds as anti-cancer agents.

Abstract
Tellurium is a rare element, which has been regarded as a toxic, non-essential trace element; its biological role, if any, has not been clearly established to date. The investigation of therapeutic activities of tellurium compounds is rather limited in the literature, despite the relative abundance of tellurium in the human body. Nevertheless, the varied activities of tellurium agents in both malignant and normal cells are extremely exciting, though very complex. Not surprisingly, an increased interest in tellurium among biological chemists and pharmacists has fuelled the search for more and more diverse tellurium compounds. The present review will focus on two small inorganic tellurium complexes, ammonium trichloro(dioxoethylene-O,O')tellurate (AS101) and Octa-O-bis-(R,R)-tartarate ditellurane (SAS), thoroughly investigated by us, converging at their anti-cancer properties, and elucidating their mechanism of action. AS101 is probably the most extensively studied synthetic tellurium compound from the standpoint of its biological activity. It is a potent immunomodulator (both in vitro and in vivo) with a variety of potential therapeutic applications. It is probably the only tellurium compound to be tested in phase I/II clinical studies in cancer patients. The effects of AS101 and SAS are primarily caused by their specific Te(IV) redox-modulating activities enabling the inactivation of cysteine proteases such as cathepsin B, inhibition of specific tumor survival proteins like survivin, or obstruction of tumor IL-10 production. All of these have profound consequences regarding anti-tumor activity or sensitization of tumors to chemotherapy. These properties, coupled with the excellent safety profile of the compounds, suggest promising anti-cancer therapeutic potential for tellurium compounds such as AS101 or SAS.
AuthorsBenjamin Sredni
JournalSeminars in cancer biology (Semin Cancer Biol) Vol. 22 Issue 1 Pg. 60-9 (Feb 2012) ISSN: 1096-3650 [Electronic] England
PMID22202556 (Publication Type: Journal Article, Review)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Adjuvants, Immunologic
  • Antineoplastic Agents
  • Cysteine Proteinase Inhibitors
  • Ethylenes
  • Immunologic Factors
  • Organometallic Compounds
  • Tartrates
  • octa-O-bistartarate ditellurane
  • Interleukin-10
  • ammonium trichloro(dioxoethylene-O,O'-)tellurate
Topics
  • Adjuvants, Immunologic (pharmacology, therapeutic use)
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Cysteine Proteinase Inhibitors (pharmacology, therapeutic use)
  • Dogs
  • Ethylenes (pharmacology, therapeutic use)
  • Humans
  • Immunologic Factors (physiology)
  • Immunomodulation (physiology)
  • Interleukin-10 (antagonists & inhibitors, metabolism)
  • Mice
  • Neoplasms (drug therapy)
  • Organometallic Compounds (pharmacology, therapeutic use)
  • Rats
  • Tartrates (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: